Clinical and Demographic Characteristics of Uveitis Patients: Eastern Black Sea Region Sample

Yıl 2024, Cilt: 14 Sayı: 2, 190 - 195, 29.08.2024

Nurcan Gürsoy , Nurettin Akyol , Adem Türk

Öz

Aim: Uveitis is one of the leading causes of visual impairment worldwide. This study aims to delineate the demographic and clinical characteristics of uveitis patients who underwent treatment and monitoring at our facility.
Material and Methods: A retrospective examination was conducted on the medical records of uveitis patients monitored at the Uvea-Behçet Unit of Karadeniz Technical University Faculty of Medicine Farabi Hospital between 1997 and 2020. Four hundred and fifty uveitis patients, whose records comprehensively met the study criteria, were evaluated for analysis.
Results: Females constituted 56.2% (n=253) while males represented 43.8% (n=197) of the study group. Patients exhibited a mean age of 35.85±16.79 years. The predominant clinical presentation was a decline in visual acuity reported by 84.9% (n=382) of the patients. Idiopathic uveitis emerged as the most prevalent subtype accounting for 23.5% (n=106) of cases. Topical steroids were the primary treatment administered to 78.4% (n=353) of the study group. Six hundred eleven of a total of 900 eyes were involved. Anatomically, anterior uveitis was the most common form in all eyes, with 38.7% (n=349). Of the eyes with involvement, 59.1% (n=367) fully recovered, while 38.5% (n=239) experienced symptom management with ongoing treatment, and 2.4% (n=15) of patients were non-responsive to treatment.
Conclusion: The prevalence, subtype distribution, and clinical manifestations of uveitis can exhibit regional variations. This study demonstrates the demographic and clinical characteristics of uveitis patients in the Eastern Black Sea Region.

Anahtar Kelimeler

uveitis, uveal diseases; uveitis therapy;, uveitis complications

Kaynakça

• 1. Yılmaz SG. Skleritler ve üveitler. Ege Tıp Dergisi. 2021:61–9.
• 2. de Smet MD, Taylor SR, Bodaghi B, Miserocchi E, Murray PI, et al. Understanding uveitis: the impact of research on visual outcomes. Progress in Retinal and Eye Research. 2011;30(6):452–70.
• 3. Muñoz-Fernández S, Martín-Mola E. Uveitis. Best Practice & Research Clinical Rheumatology. 2006;20(3):487–505.
• 4. Miserocchi E, Fogliato G, Modorati G, Bandello F. Review on the worldwide epidemiology of uveitis. European Journal of Ophthalmology. 2013;23(5):705–17.
• 5. Thorne JE, Suhler E, Skup M, Tari S, Macaulay D, et al. Prevalence of noninfectious uveitis in the United States: a claims-based analysis. JAMA Ophthalmology. 2016;134(11):1237–45.
• 6. Acharya NR, Tham VM, Esterberg E, Borkar DS, Parker JV, et al. Incidence and prevalence of uveitis: results from the Pacific Ocular Inflammation Study. JAMA Ophthalmology. 2013;131(11):1405–12.
• 7. Sızmaz S, Akova YA, Güngör SG, Öktem Ç, Yaycıoğlu RA. Üveit olgularımızın etyolojik ve klinik özellikleri. Turkish Journal of Ophthalmology / Turk Oftalmoloji Dergisi. 2010;40(5).
• 8. Daylan AE. Kliniğimizde takipli üveitik glokom hastalarında medikal ve cerrahi tedavi sonuçlarımız, uzmanlık tezi: Akdeniz Üniversitesi 2018.
• 9. Ferrara M, Eggenschwiler L, Stephenson A, Montieth A, Nakhoul N, et al. The challenge of pediatric uveitis: tertiary referral center experience in the United States. Ocular immunology and inflammation. 2019;27(3):410–7.
• 10. Yalçındağ FN, Özdal PC, Özyazgan Y, Batıoğlu F, Tugal-Tutkun I, et al. Demographic and clinical characteristics of uveitis in Turkey: the first national registry report. Ocular Immunology Inflammation. 2018;26(1):17–26.
• 11. Tsirouki T, Dastiridou A, Symeonidis C, Tounakaki O, Brazitikou I, et al. A focus on the epidemiology of uveitis. Ocular Immunology Inflammation. 2018;26(1):2–16.
• 12. García-Aparicio Á, García de Yébenes MJ, Otón T, MuñozFernández S. Prevalence and incidence of uveitis: a systematic review and meta-analysis. Ophthalmic Epidemiology. 2021;28(6):461–8.
• 13. Rathinam S, Namperumalsamy P. Global variation and pattern changes in epidemiology of uveitis. Indian Journal of Ophthalmology. 2007;55(3):173.
• 14. Khairallah M, Yahia SB, Ladjimi A, Messaoud R, Zaouali S, et al. Pattern of uveitis in a referral centre in Tunisia, North Africa. Eye. 2007;21(1):33–9.
• 15. Espinosa G, Muñoz-Fernández S, García Ruiz de Morales JM, Herreras JM, Cordero-Coma M. Treatment recommendations for non-infectious anterior uveitis. Med Clin (Barc). 2017;149(12):552. e1–e12.
• 16. Gamalero L, Simonini G, Ferrara G, Polizzi S, Giani T, et al. Evidence-based treatment for uveitis. Isr Med Assoc J. 2019;21(7):475–9.
• 17. Pacheco PA, Taylor SR, Cuchacovich MT, Diaz GV. Azathioprine in the management of autoimmune uveitis. Ocular Immunology Inflammation. 2008;16(4):161–5.
• 18. Mili-Boussen I, Zitouni M, Ammous I, Letaief I, Errais K, et al. Azathioprine for glucocorticoid resistant noninfectious uveitis. La Tunisie Medicale. 2015;93(3):158–63.
• 19. Siddique SS, Suelves AM, Baheti U, Foster CS. Glaucoma and uveitis. Survey of ophthalmology. 2013;58(1):1–10.
• 20. Al Rubaie K, Al Dhahri H, Al Fawaz A, Hemachandran S, Mousa A, et al. Incidence and risk factors for developing glaucoma among patients with uveitis in a university-based tertiary referral center in Riyadh, Saudi Arabia. Ocular Immunology Inflammation. 2016;24(5):571–8.
• 21. Dick AD, Tundia N, Sorg R, Zhao C, Chao J, et al. Risk of ocular complications in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis. Ophthalmology. 2016;123(3):655–62.
• 22. Arevalo JF, Lasave AF, Gupta V, Kozak I, Al Shamsi HN, et al. Clinical characteristics and treatment of 308 panuveitis patients over 10 years: results from the KKESH uveitis survey study group. Ocular Immunology Inflammation. 2019;27(8):1296304.